Last reviewed · How we verify
Celecoxib and aspirin
This combination uses celecoxib (a selective COX-2 inhibitor) and aspirin (a non-selective COX inhibitor) together to reduce inflammation and pain through complementary inhibition of cyclooxygenase enzymes.
This combination uses celecoxib (a selective COX-2 inhibitor) and aspirin (a non-selective COX inhibitor) together to reduce inflammation and pain through complementary inhibition of cyclooxygenase enzymes. Used for Cardiovascular event prevention in patients with chronic pain or arthritis requiring NSAID therapy.
At a glance
| Generic name | Celecoxib and aspirin |
|---|---|
| Sponsor | Takeda |
| Drug class | Non-steroidal anti-inflammatory drug (NSAID) combination |
| Target | COX-1 and COX-2 (cyclooxygenase enzymes) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Celecoxib selectively inhibits COX-2, reducing prostaglandin production and inflammation while theoretically sparing COX-1-mediated gastric protection. Aspirin provides additional antiplatelet and anti-inflammatory effects through non-selective COX inhibition. The combination is designed to optimize anti-inflammatory efficacy while potentially improving cardiovascular and gastrointestinal safety profiles compared to either agent alone.
Approved indications
- Cardiovascular event prevention in patients with chronic pain or arthritis requiring NSAID therapy
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Cardiovascular events
- Renal impairment
Key clinical trials
- Timed Aspirin Chronobiome Study (EARLY_PHASE1)
- The Seven Trial: Exploiting the Unfolded Protein Response (PHASE1)
- Minimal Opioid Use After Total Hip Replacement (THR) (PHASE4)
- Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS (PHASE4)
- RACIN in Patients With Advanced TIL-negative Solid Tumors (PHASE1)
- Pain Treatment With Combinations of NSAIDs (NA)
- PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer (PHASE2)
- Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celecoxib and aspirin CI brief — competitive landscape report
- Celecoxib and aspirin updates RSS · CI watch RSS
- Takeda portfolio CI